US2936024056 - Common Stock
ENSYSCE BIOSCIENCES INC
NASDAQ:ENSC (12/20/2024, 8:07:14 PM)
After market: 7.775 -0.32 (-4.01%)8.1
+0.15 (+1.89%)
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
ENSYSCE BIOSCIENCES INC
7946 Ivanhoe Avenue, Suite 201
La Jolla CALIFORNIA
P: 18582634196
CEO: Daniel B. Silvers
Employees: 7
Website: https://ensysce.com/
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Which stocks are experiencing notable movement on Friday?
Friday's session: gap up and gap down stocks
Here you can normally see the latest stock twits on ENSC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: